Moderately hypofractionated regional nodal irradiation had 6.4% three-year lymphedema
With 42.56 Gy in 16 fractions, three-year lymphedema was 6.4%, with no new events through five years.
With 42.56 Gy in 16 fractions, three-year lymphedema was 6.4%, with no new events through five years.
Ninety-five percent completed 55 Gy in 20 fractions, with encouraging outcomes in early p16-positive oropharyngeal cancer despite substantial acute toxicity.
Reduced-volume MR-guided RT caused no grade ≥3 toxicity, but two of ten patients developed in-field recurrence after five-fraction treatment.
Four-year biochemical control was similar with 65 Gy in 26 fractions and 66 Gy in 33 fractions, while gastrointestinal toxicity was higher.
Two-year sustained complete response was 36% after short-course RT and response-adapted FOLFOX4, while near-complete responses frequently regrew.
Three Quad Shot cycles caused limited high-grade toxicity, no systemic-therapy delays and frequent thoracic symptom improvement.
Recent trials report 40–61% pathologic complete response with short-course radiotherapy plus immunotherapy, but mature comparative outcomes remain unavailable.
Daily online adaptation improved pelvic target coverage during 17-fraction cervical chemoradiotherapy, with 10% grade ≥3 gastrointestinal toxicity.
Grade 2 dermatitis fell from 38.6% to 25.3% with 16-fraction whole-breast radiotherapy plus simultaneous integrated boost.
40 Gy in 15 fractions did not increase three-year arm lymphedema or compromise recurrence and mortality outcomes compared with 50 Gy.
Radiation reached 60 Gy in 15 fractions with adjuvant atezolizumab, while concurrent dosing was followed by HSV-1 reactivation in three of five patients.
BED >37.5 Gy improved symptomatic control, while 6-month local control remained 46% in frail, elderly, or metastatic rectal cancer.
High-dose-rate brachytherapy monotherapy achieved 86% biochemical control at median 13-year follow-up in localized prostate cancer.
A conventional-fractionation model produced clinically acceptable moderately hypofractionated prostate plans, with comparable overall quality and slightly reduced target homogeneity.